Information:
Error:
ID
22648
Description
Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00398281
Link
https://clinicaltrials.gov/show/NCT00398281
Keywords
Versions (1)
- 6/8/17 6/8/17 -
Uploaded on
June 8, 2017
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Prostate Cancer NCT00398281
Eligibility Prostate Cancer NCT00398281
- StudyEvent: Eligibility
Similar models
Eligibility Prostate Cancer NCT00398281
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Prostate carcinoma Suspected
Item
suspected prostate cancer due to 1 of the following criteria:
boolean
C0600139 (UMLS CUI [1,1])
C0750491 (UMLS CUI [1,2])
C0750491 (UMLS CUI [1,2])
Digital Rectal Examination Abnormal
Item
prior abnormal digital rectal exam
boolean
C1384593 (UMLS CUI [1,1])
C0205161 (UMLS CUI [1,2])
C0205161 (UMLS CUI [1,2])
Raised prostate specific antigen
Item
elevated prostate-specific antigen (psa) ≥ 2.6 ng/ml within the past 90 days
boolean
C0178415 (UMLS CUI [1])
PSA Velocity
Item
psa velocity > 0.75 ng/ml/year
boolean
C1518823 (UMLS CUI [1])
Transrectal endoscopic ultrasound with biopsy Planned
Item
must be planning to undergo a transrectal ultrasound with biopsy
boolean
C2181472 (UMLS CUI [1,1])
C1301732 (UMLS CUI [1,2])
C1301732 (UMLS CUI [1,2])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Physical Well-being | Examination Transrectal Prolonged | Transrectal biopsy of prostate
Item
must be in adequate physical health to tolerate a prolonged transrectal examination and biopsy
boolean
C0517226 (UMLS CUI [1])
C0031809 (UMLS CUI [2,1])
C0524447 (UMLS CUI [2,2])
C0439590 (UMLS CUI [2,3])
C0401641 (UMLS CUI [3])
C0031809 (UMLS CUI [2,1])
C0524447 (UMLS CUI [2,2])
C0439590 (UMLS CUI [2,3])
C0401641 (UMLS CUI [3])
Unstable status Excluded | Illness Severe Excluded | Moribund Excluded
Item
must not be clinically unstable, severely ill, or moribund
boolean
C0443343 (UMLS CUI [1,1])
C2828389 (UMLS CUI [1,2])
C0221423 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C2828389 (UMLS CUI [2,3])
C0424547 (UMLS CUI [3,1])
C2828389 (UMLS CUI [3,2])
C2828389 (UMLS CUI [1,2])
C0221423 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C2828389 (UMLS CUI [2,3])
C0424547 (UMLS CUI [3,1])
C2828389 (UMLS CUI [3,2])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
Biopsy of prostate
Item
more than 30 days since prior biopsy of the prostate
boolean
C0194804 (UMLS CUI [1])
Aspirin | Anticoagulants
Item
more than 1 week since prior acetylsalicylic acid or blood thinner
boolean
C0004057 (UMLS CUI [1])
C0003280 (UMLS CUI [2])
C0003280 (UMLS CUI [2])
Study Subject Participation Status | Investigational New Drugs
Item
more than 30 days since prior participation in a clinical trial involving an investigational drug
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0013230 (UMLS CUI [2])
Prostate carcinoma Prior Therapy Absent
Item
no prior therapy for prostate cancer
boolean
C0600139 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C1514463 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
5-alpha Reductase Inhibitors Additional Absent
Item
no other concurrent 5-alpha reductase inhibitor
boolean
C2936788 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C1524062 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])